Loading...

Financial Statements

Selecta Biosciences Inc.

Selecta Biosciences Inc. (SELB)

Healthcare

Income Statement

Download SELB income statement Download SELB income statement
Year 20142015201620172018
Revenue -----
Cost of Revenue -----
Gross Profit -----
R&D Expenses 10.4922.9829.7045.1647.69
Sales, General and Administrative Expense 7.958.3413.0518.8318.24
Operating Expenses 18.4431.3242.7563.9965.92
Operating Income -18.44-31.32-42.75-63.99-65.92
Interest Expense 0.550.951.251.211.49
Earnings before Tax -12.88-25.17-36.21-65.32-65.34
Income Tax Expense -----
Net Income -12.88-25.17-36.21-65.32-65.34
Net Income - Non-Controlling int -----
Net Income - Discounted ops -----
Net Income Com -12.88-25.17-36.21-65.32-65.34
Preferred Dividends 3.497.334.57--
Earnings Per Share Basic -7.84-15.13-3.89-3.20-2.92
Earnings Per Share Diluted -7.84-15.13-3.89-3.20-2.92
Weighted Average Shares Outstanding 2.092.1510.4920.4322.39
Weighted Average Shares Outstanding (Diluted) 2.092.1510.4920.4322.39
Dividend per Share -----
Gross Margin -----
EBITDA Margin -----
EBIT Margin -----
Profit Margin -----
Free Cash Flow margin -----
EBITDA -11.46-23.18-34.16-63.37-62.87
EBIT -12.33-24.23-34.96-64.11-63.84
Consolidated Income -12.88-25.17-36.21-65.32-65.34
Earnings Before Tax Margin -----
Net Profit Margin -----

Balance Sheet Statement

Download SELB income statement Download SELB income statement
Year 20142015201620172018
Cash and cash equivalents 18.9432.7959.0570.7037.40
Short-term investments -4.1325.4825.94-
Cash and short-term investments 18.9436.9184.5396.6437.40
Receivables 0.670.820.21--
Inventories -----
Property, Plant & Equipment Net 1.982.032.052.092.13
Goodwill and Intangible Assets -----
Long-term investments -----
Tax assets -----
Total non-current assets 6.7214.5420.6438.3114.76
Total current assets 3.123.912.482.422.41
Total assets 22.2342.8289.30101.1044.48
Payables 0.352.183.881.611.10
Short-term debt 2.58-4.07-21.39
Total current liabilities 9.237.2913.7110.9735.14
Long-term debt 4.8211.867.9821.04-
Total debt 7.4011.8612.0421.0421.39
Deferred revenue 4.383.6114.2816.7114.78
Tax Liabilities -----
Deposit Liabilities -----
Total non-current liabilities 6.7214.5420.6438.3114.76
Total liabilities 15.9521.8434.3449.2949.90
Other comprehensive income -3.88-4.99-4.52-4.42-4.56
Retained earnings (deficit) -83.88-111.51-151.58-216.90-280.40
Total shareholders equity -87.75-116.4954.9651.81-5.42
Investments -4.1325.4825.94-
Net Debt -11.54-25.06-72.49-75.60-16.02
Other Assets -0.501.182.072.044.67
Other Liabilities 6.305.115.769.3712.66

Cash Flow Statement

Download SELB income statement Download SELB income statement
Year 20142015201620172018
Depreciation & Amortization 0.861.040.800.750.97
Stock-based compensation 1.221.132.054.085.71
Operating Cash Flow -12.69-22.46-19.76-52.03-59.16
Capital Expenditure -0.23-1.16-0.58-0.73-0.79
Acquisitions and disposals -----
Investment purchases and sales --3.52-21.52-1.3726.06
Investing Cash Flow -----
Insurance (repayment) of debt -----
Insurance (buybacks) of shares -----
Dividend payments -----
Financing Cash Flow 24.7743.9167.6666.020.70
Effect of forex changes on cash -3.32-1.020.460.08-0.15
Net cash flow / Change in cash 8.5415.7426.2711.98-33.34
Free Cash Flow -12.91-23.63-20.34-52.76-59.95
Net Cash/Marketcap 0.000.000.000.000.00

Retained Earning Schedule

Retained Earning Schedule

Year 20142015201620172018
Retained Earnings (Previous Year) --84-112-152-217
Net Income -13-25-36-65-65
Stock Dividends -71-2-4-2
Divident Paid -----
Retained Earnings -84-112-152-217-280

PPE Schedule

Year 20142015201620172018
Gross PPE -2222
Annual Depreciation 21111
Capital Expenditure -0-1-1-1-1
Net PPE 22222

Intangible and Goodwill Schedule

Intangible and Goodwill Schedule

Year 20142015201620172018
Intangible and Goodwill (Previous Year) -----
New Purchases --4-22-126
Intangible and Goodwill -----

Selecta Biosciences Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Selecta Biosciences Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.